drugset / Trial / NCT06481579
A Study of IVX-A12 in Adults Participants
RandomizedParallel-groupTriple-blindOther
Summary
The primary purpose of this study is to assess the immunogenicity and safety of IVX-A12 in adults 60 years of age and older.
Timeline
- Start
- 2024-06-10
- Primary completion
- 2024-07-17
- Completion
- 2024-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Arexvy | Vaccine | — | Intramuscular |
| Subject | IVX-A12 | Vaccine | 300 ug | Intramuscular |
Indications
No indication recorded.